Improving efficiency of ALS clinical trials: a sponsor's perspective
Amyotroph Lateral Scler Other Motor Neuron Disord
.
2002:3 Suppl 1:S7-8.
doi: 10.1080/146608202320374138.
Authors
S Markabi
1
,
J Schadrack
Affiliation
1
Novartis Pharma AG, 4002 Basel, Switzerland.
PMID:
12396792
DOI:
10.1080/146608202320374138
No abstract available
MeSH terms
Amyotrophic Lateral Sclerosis / drug therapy*
Biomarkers
Clinical Trials as Topic*
Dose-Response Relationship, Drug
Humans
Research Design
Substances
Biomarkers